Clinical Kidney Journal, 2017, vol. 10, no. 5, 679–687 doi: 10.1093/ckj/sfx036 Advance Access Publication Date: 26 May 2017 CKJ Review
CKJ REVIEW
Lesinurad: what the nephrologist should know ~ o1,2,3, Binbin Zheng-Lin1,2, Lara Valin ~ o-Rivas1,2,3, Maria Dolores Sanchez-Nin ~ o3,4, Marian Ana Belen Sanz1,2,3, Adrian Mario Ramos1,2,3, Jose Lun Goicoechea3,4 and Alberto Ortiz1,2,3 1
Department of Nephrology, IIS-Fundacion Jimenez Diaz, School of Medicine, Universidad Autonoma de ~ igo Alvarez de Toledo (FRIAT), Madrid, Spain, 3REDINREN, Madrid, Madrid, Madrid, Spain, 2Fundacion Renal In 4 ~o n, Madrid, Spain Spain and Servicio de Nefrologıa, Hospital General Universitario Gregorio Maran Correspondence and offprint requests to: Alberto Ortiz; E-mail: [email protected]
Abstract Lesinurad is an oral inhibitor of the monocarboxylic/urate transporter URAT1 encoded by the SLC22A12 gene. Market authorization was granted in February 2016 in Europe and December 2015 in the USA. As a potentially nephrotoxic uricosuric drug acting on the kidney, nephrologists should become familiar with its indications and safety profile. The approved indication is treatment of gout in combination with a xanthine oxidase (XO) inhibitor in adult patients who have not achieved target serum uric acid levels with an XO inhibitor alone. It is not indicated for asymptomatic hyperuricaemia or for patients with estimated creatinine clearance
CKJ REVIEW
Lesinurad: what the nephrologist should know ~ o1,2,3, Binbin Zheng-Lin1,2, Lara Valin ~ o-Rivas1,2,3, Maria Dolores Sanchez-Nin ~ o3,4, Marian Ana Belen Sanz1,2,3, Adrian Mario Ramos1,2,3, Jose Lun Goicoechea3,4 and Alberto Ortiz1,2,3 1
Department of Nephrology, IIS-Fundacion Jimenez Diaz, School of Medicine, Universidad Autonoma de ~ igo Alvarez de Toledo (FRIAT), Madrid, Spain, 3REDINREN, Madrid, Madrid, Madrid, Spain, 2Fundacion Renal In 4 ~o n, Madrid, Spain Spain and Servicio de Nefrologıa, Hospital General Universitario Gregorio Maran Correspondence and offprint requests to: Alberto Ortiz; E-mail: [email protected]
Abstract Lesinurad is an oral inhibitor of the monocarboxylic/urate transporter URAT1 encoded by the SLC22A12 gene. Market authorization was granted in February 2016 in Europe and December 2015 in the USA. As a potentially nephrotoxic uricosuric drug acting on the kidney, nephrologists should become familiar with its indications and safety profile. The approved indication is treatment of gout in combination with a xanthine oxidase (XO) inhibitor in adult patients who have not achieved target serum uric acid levels with an XO inhibitor alone. It is not indicated for asymptomatic hyperuricaemia or for patients with estimated creatinine clearance
![[Echocardiography - What you should know?].](/assets/img/hold.png)
